BDB Pitmans supports Cambridge Molecular Diagnostics Ltd with fundraising and conversion of a Future Fund loan

BDB Pitmans’ Cambridge corporate team has advised existing clients Cambridge Molecular Diagnostics Ltd in relation to fundraising and the conversion of a Future Fund loan.

Cambridge Molecular Diagnostics, who trade under the name Swift DX, are a researcher and developer of biotechnology who work to improve global diagnostics by creating ultra-sensitive testing kits such as for mycoplasma detection, hepatitis C testing and early HIV detection tests.

The Future Fund was a government scheme operated by the British Business Bank that provided loans to UK-based companies during the Coronavirus pandemic, as long as they were matched by at least equal private investment.

BDB Pitmans team was led by corporate partner Duncan Walker, assisted by Associate Ross Fletcher.

Andrew Taylor, CFO at Cambridge Molecular Diagnostics Ltd, commented:

‘This fundraising marks an exciting next step for Cambridge Molecular Diagnostics, and we are grateful for the highly responsive and considered professional expertise that BDB Pitmans provided us.’

Duncan Walker concluded,

‘We are delighted to have been able to assist Cambridge Molecular Diagnostics with their fundraising efforts and look forward to working with them in the future as they continue their growth journey.’